No Effect of Antidepressant Treatment on Elevated Serum Ceruloplasmin Level in Patients with First-Episode Depression: A Longitidunal Study

Archives of Medical Research

Volumn 43, Issue 4, 2012, Pages 294-297

  Kaya, Mehmet Cemal ^a   Bez, Yasin ^a   Selek, Salih ^b   Fatih Karababa, Ibrahim ^b   Bulut, Mahmut ^a   Savaş, Haluk A ^b   Çelik, Hakim ^c   Herken, Hasan ^d  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

^d PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antidepressant treatment; Antioxidant; Ceruloplasmin; Depression; Oxidative stress

Indexed keywords

CERULOPLASMIN; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HAMILTON SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NATURALISTIC INQUIRY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CERULOPLASMIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 84864091530     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.05.006     Document Type: Article

References (28)

1. Ferenci P. Pathophysiology and clinical features of Wilson's disease. Metab Brain Dis 2004, 19:229-239.
2. Mukhopadhyay C.K., Ehrenwald E., Fox P.L. Ceruloplasmin enhances smooth muscle cell- and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism. J Biol Chem 1996, 271:14773-14778.
3. Floris G., Medda R., Padiglia A., et al. The physiopathological significance of ceruloplasmin. A possible therapeutic approach. Biochem Pharmacol 2000, 60:1735-1741.
4. Yoshida K., Kaneko K., Miyajima H., et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 2000, 175:91-95.
5. Berg D., Hochstrasser H., Schweitzer K.J., et al. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res 2006, 9:1-13.
6. Wiedemann K. Biomarkers in development of psychotropic drugs. Dialogues Clin Neurosci 2011, 13:225-234.
7. Crupi R., Marino A., Cuzzocrea S. New therapeutic strategy for mood disorders. Curr Med Chem 2011, 18:4284-4298.
8. Virit O., Altindaĝ A., Selek S., et al. Increased plasma ceruloplasmin levels in schizophrenia. Bull Clin Psychopharmacol 2008, 18:282-287.
9. Virit O., Selek S., Bulut M., et al. High ceruloplasmin levels are associated with obsessive compulsive disorder: a case control study. Behav Brain Funct 2008, 18:52.
10. Maes M., Scharpé S., Van Grootel L., et al. Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 1992, 24:183-192.
11. Bekaroĝlu M., Bilici M., Deĝer O., et al. Effect of antidepressant treatment on acute phase protein levels in patients with depression. Turk Psikiyatri Derg 1997, 8:260-265.
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
13. Akdemir A., Turkcapar M.G., Orsel S.D., et al. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001, 42:161-165.
14. Tedlow J., Fava M., Uebelacker L., et al. Outcome definitions and predictors in depression. Psychother Psychosom 1998, 67:266-270.
15. Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998, 44:2313-2319.
16. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004, 37:112-119.
17. Pazvantoglu O., Selek S., Okay I.T., et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009, 63:693-700.
18. Twomey P.J., Viljoen A., House I.M., et al. Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin Chem 2005, 51:1558-1559.
19. Schmid K., Nolte-Zenker B., Patzer J., et al. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 2001, 34:66-72.
20. Wolf T.L., Kotun J., Meador-Woodruff J.H. Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr Res 2006, 86:167-171.
21. Jones C.E., Underwood C.K., Coulson E.J., et al. Copper induced oxidation of serotonin: analysis of products and toxicity. J Neurochem 2007, 102:1035-1043.
22. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
23. Hesse S., Barthel H., Hermann W., et al. Regional serotonin transporter availability and depression are correlated in Wilson's disease. J Neural Transm 2003, 110:923-933.
24. Eggers B., Hermann W., Barthel H., et al. The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson's disease. J Neurol 2003, 250:576-580.
25. Cumurcu B.E., Ozyurt H., Etikan I., et al. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009, 63:639-645.
26. Selek S., Dalkilic A., Kaya M.C., et al. The relationship of oxidative metabolism to treatment response in major depression: a biological basis for treatment duration. Neurol Psychiatr Brain Res 2012, 18:15-18.
27. Selek S., Herken H., Bulut M., et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatr 2008, 32:487-491.
28. Akiskal H.S. Mood disorders. Kaplan & Sadock's Comprehensive Text Book of Psychiatry 2009, 1649. Lippincott Williams & Wilkins, Philadelphia. 9th ed. H.I. Kaplan, B.J. Sadock (Eds.).